136 indexable Life Sciences companies headquartered in Flanders, Belgium, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $1.7B across 69 funded companies.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
MRM Health
Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases |
$15.1M | — | Series B | Grant (prize money) May 2026 | 43 | 2020 | ↑ Active |
| 2 |
AgomAb Therapeutics
Developer of monoclonal antibody molecules for multiple disorders |
$327M | — | Public | Series D Oct 2024 | 23 | 2017 | ↑ Active |
| 3 |
PanTera
Provider of actinium-225 isotopes for targeted cancer therapy development and production |
$139.9M | — | Series A | Conventional Debt Sep 2024 | — | 2022 | ↑ Active |
| 4 |
Aspect Analytics
Developer of mass spectroscopy integrated bioinformatics software for molecular imaging |
$11.7M | — | Series A | Series A Sep 2025 | 2 | 2018 | ↑ Active |
| 5 |
Augustine Therapeutics
Developer of therapeutics for neuromuscular diseases |
$23.2M | — | Series A | Series A Mar 2025 | 1 | 2019 | ↑ Active |
| 6 |
Azalea Vision
Developer of technology for people with high light sensitivity and ocular disorders |
$9.4M | — | Series A | Series A Apr 2025 | 7 | 2018 | ↑ Active |
| 7 |
Nobi
Provider of a smart lamp for fall detection of elderly people |
$14.5M | — | Series B | Series B Jan 2025 | 12 | 2018 | ↑ Active |
| 8 |
Biocartis
Developer of molecular assays for the detection of various diseases |
$305.3M | — | Public | Post IPO Sep 2022 | 43 | 2007 | — |
| 9 |
Monsana
Provider of digital platform that utilizes artificial intelligence to streamline the search process for clinical trials |
$588.4K | — | Seed | Seed Sep 2025 | — | 2024 | ↑ Active |
| 10 |
Indigo
Needle free glucose monitoring technology |
$52.6M | — | Series B | Grant (prize money) Oct 2023 | 33 | 2016 | — |
| 11 |
eTheRNA
Developer of mRNA-based immunotherapies for cancer and infectious diseases |
$103.9M | — | Series B | Series B Aug 2022 | 80 | 2013 | — |
| 12 |
EXO Biologics
Developer of cell-based therapeutics |
$17.1M | — | Series A | Series A Apr 2024 | 21 | 2019 | — |
| 13 |
FlexGRIP
Provider of catheter cushion and stabilisation device |
$11M | — | Series A | Series A Jun 2024 | 2 | 2011 | — |
| 14 |
ExeVir Bio
Provider of antibody-based therapies to monitor viral infections |
$49.6M | — | Series A | Venture Debt Jan 2023 | 11 | 2020 | — |
| 15 |
Dualyx
Developer of immune modulators for treating auto-immune diseases |
$43.4M | — | Series A | Series A May 2023 | 7 | 2019 | — |
| 16 |
argenx
Developer of antibody-based drugs to treat autoimmune diseases and cancer |
$61.9M | — | Public | Post IPO Mar 2022 | 355 | 2008 | — |
| 17 |
Devgen
An agritech company developing hybrid seeds and crop protection solutions |
$71M | — | Acquired | Grant (prize money) Jan 2021 | 35 | 1997 | — |
| 18 |
ActoGeniX
Engineering microbes for in situ expression and secretion of novel biotherapeutic proteins and peptides. |
$57.2M | — | Acquired | Series B Apr 2013 | 5 | 2006 | — |
| 19 |
Rejuvenate Biomed
Developer of drugs for treating sarcopenia |
$22M | — | Series B | Series B Oct 2021 | 6 | 2017 | — |
| 20 |
Bio Base Europe Pilot Plant
Provider of biobased product process development, scale-up, and custom manufacturing |
$15.1M | — | Funding Raised | Grant (prize money) Jun 2021 | 146 | 2008 | — |
| 21 |
Allegro
Developer of regenerative medicine for rheumatology and orthopedics |
$6.1M | — | Series A | Series A Apr 2023 | 3 | 2020 | — |
| 22 |
Pronota
Provider of diagnostics for heart failure, pre-eclampsia, and sepsis |
$34.7M | — | Acqui-Hired | Series C Dec 2012 | 2 | 2004 | — |
| 23 |
Inbiose
Contract manufacturer of specialty carbohydrates |
$18M | — | Funding Raised | Conventional Debt Jul 2021 | 43 | 2013 | — |
| 24 |
Morrow Eyewear
Provider of auto focal lens for refractive errors in eyes |
$10M | — | Series A | Series A Jul 2022 | 37 | 2016 | — |
| 25 |
Complix
Developer of protein based therapeutics using proprietary alpha-body technology |
$24.4M | — | Series B | Grant (prize money) Dec 2017 | 13 | 2008 | — |
| 26 |
Galapagos
Developer of small molecule drugs for immunology and oncology |
$26.1M | — | Public | Post IPO Nov 2019 | 449 | 1999 | — |
| 27 |
FOx Biosystems
Developer of fiber optic bio-sensing technology based on surface plasmon resonance |
$4.5M | — | Series A | Grant (prize money) Dec 2022 | 9 | 2017 | — |
| 28 |
OncoMethylome
Diagnostics for early detection of cancer |
$33.9M | — | Series B | Series B Nov 2005 | 3 | 2003 | — |
| 29 |
Apitope
Developer of therapeutic peptides for the treatment of autoimmune and allergic diseases |
$26.6M | — | Series B | Series B Sep 2015 | 6 | 2002 | — |
| 30 |
Guud
Developer of nutritional supplements for women health |
$2.3M | — | Seed | Seed Jul 2023 | 1 | 2020 | — |
| 31 |
Watcherr
Provider of medical alert devices for elderly people |
$2.2M | — | Seed | Seed Jul 2023 | 3 | 2013 | — |
| 32 |
Amakem
Kinase inhibitors developing therapeutics for the treatment of serious eye conditions. |
$25.4M | — | Deadpooled | Series A Sep 2011 | 23 | 2010 | — |
| 33 |
Ontoforce
Provider of semantic search platform for pharmaceutical and biotech research |
$12.7M | — | Series B | Series B Jan 2018 | 31 | 2011 | — |
| 34 |
MyCartis
Provider of bio-marker discovery platform for immunodiagnostics |
$19.6M | — | Deadpooled | Series A Sep 2014 | 2 | 2006 | — |
| 35 |
OCTIMET Oncology
Developer of MET kinase inhibitors for the treatment of cancer |
$12.1M | — | Series A | Grant (prize money) Aug 2018 | 1 | 2016 | — |
| 36 |
Multiplicom
Provider of molecular diagnostics assays for cancer and prenatal testing |
$10.4M | — | Acquired | Grant (prize money) May 2016 | 123 | 2011 | — |
| 37 |
Trince
Developer of cell transfection machinery |
$4.5M | — | Series A | Series A Dec 2021 | 3 | 2019 | — |
| 38 |
Trinean
UV/VIS spectrometry solutions |
$9.4M | — | Acqui-Hired | Grant (prize money) Jan 2015 | 19 | 2006 | — |
| 39 |
BioStrand
AI-powered biotherapeutic platform for antibody discovery |
$2.2M | — | Seed | Grant (prize money) May 2022 | 7 | 2019 | — |
| 40 |
Perseus Biomics
Provider of microbiome analysis technology for delivering precise microbiome profiles |
$3M | — | Funding Raised | Grant (prize money) Oct 2021 | 13 | 2020 | — |
| 41 |
Pharma Diagnostics
Absorption plate-based LSPR assay for analyzing biomolecular interactions |
$7.4M | — | Series B | Series B Jan 2010 | 8 | 2007 | — |
| 42 |
RheaVita
Developer of an instrument for continuous freeze drying |
$3.1M | — | Series A | Series A Jun 2021 | 4 | 2018 | — |
| 43 |
Biogazelle
Transcriptomics-based diagnostics and therapeutics, and qPCR software. |
$3.7M | — | Acquired | Grant (prize money) Jan 2020 | 20 | 2007 | — |
| 44 |
ADx NeuroSciences
Biomarker assays for neurodegenerative diseases |
$3.2M | — | Acquired | Grant (prize money) Nov 2019 | 14 | 2011 | — |
| 45 |
Moonbird
Provider of smart devices for monitoring heart rate or breathing |
$1.7M | — | Seed | Seed Nov 2021 | 6 | 2019 | — |
| 46 |
Bio INX
Provider of diverse 3D printing inks |
$500.6K | — | Seed | Grant (prize money) Sep 2022 | — | 2022 | — |
| 47 |
DoseVue
Provider of ophthalmic devices |
$1.6M | — | Deadpooled | Grant (prize money) Jan 2020 | 1 | 2013 | — |
| 48 |
Dendrite
Dendrite International provides services and software for managing and analyzing sales efforts for the pharmaceutical and other life sciences industries. |
$3M | — | Acquired | Sep 1991 | 2,534 | 1986 | — |
| 49 |
Qallo
Online retailer of flavored powder blends designed to enhance water |
$1.3M | — | Seed | Seed Feb 2021 | 2 | 2020 | — |
| 50 |
Novosanis
Sampling and Intradermal Injection device |
$2.1M | — | Acquired | Seed Jan 2017 | 16 | 2013 | — |
Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases. The company utilizes a proprietary platform to design and manufacture microbial therapeutics. Optimized consortia are developed through a bioinformatics-guided discovery engine. The company focuses on creating therapeutics with disease-modifying potential. Clinical programs include inflammatory bowel diseases, with prec
Developer of monoclonal antibody molecules for multiple disorders. The company has developed the monoclonal antibody molecules called agomAbs which stimulates the molecular and cellular repair mechanisms. It helps in organ function for patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases.
Provider of actinium-225 isotopes for targeted cancer therapy development and production. It focuses on enabling the widespread use of radiopharmaceuticals for personalized tumor treatment. The company aims to secure large-scale production of actinium-225, a promising alpha-emitting radioisotope. Its ultimate goal is to improve the accessibility of innovative cancer therapy based on actinium-225 and theranostics. The
Aspect Analytics is the developer of mass spectroscopy integrated bioinformatics software for molecular imaging. Its services include bioinformatics, machine learning, AI and software engineering enables us to develop optimal data analysis strategies and MSI induces a true data deluge, requiring effective solutions for data management, storage, and analysis among others.
Developer of therapeutics for neuromuscular diseases. It offers a lead product small molecule inhibitors of HDAC6, a validated molecular target with strong biological rational for neuromuscular and neurodegenerative disorders, cardiometabolism, inflammatory and autoimmune diseases.
Developer of technology for people with high light sensitivity and ocular disorders. The company has developed an active light management system, embedded inside a contact lens. It helps in the treatment of iris deficiencies, high order aberrations, light sensitivity, and photophobia.
Provider of a smart lamp for fall detection of elderly people. The lamp support caregivers in a residential care center to monitor elder's and resident's fall. The integrated device can monitor blood pressure and offers automated lighting when rising from the bed. The device can continuously measurements of room temperature or air quality. The features include fall prevention, night watch, air quality monitoring, smo
Developer of molecular assays for the detection of various diseases. The company has developed its proprietary micro-technology platform that is based on integrated molecular and immunodiagnostics technology. It is used for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. It can also be used in the analysis of biomolecules associated wit
Provider of digital platform that utilizes artificial intelligence to streamline the search process for clinical trials. It offers an AI assistant for doctors and patients that seamlessly links patients with clinical trials, accelerating medical research, and enhancing patient care.
Indigo is developing a needle-free continuous glucose monitoring technology using photonics technologies. Indigo is based in Ghent, Belgium, where it benefits from access to Ghent University and more specifically the Photonics Research Group and the NB-Photonics consortium.
Developer of mRNA-based immunotherapies for cancer and infectious diseases. It offers proprietary mRNA-based TriMix technology that has three mRNA molecules (caTLR4, CD40L, CD70) boost immune response through the dendritic cell pathway which has applications in indications of Melanoma and breast cancer.
Developer of cell-based therapeutics. The company is developing extracellular vesicles and exosome drugs that can replace stem cell therapies. These extracellular vesicles are developed from mesenchymal stem cells. Extracellular vesicles function includes intracellular communication, transfer of proteins, lipids, and genetic material. These drugs are developed for inflammatory diseases, autoimmune diseases, and acute
Europa
PMV
EQT
LRM
Qbic Fund
VIB
imec.istart
IWT
EIT Health
Gimv
Life Sciences Partners
Start it @KBC
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-20.
_1553572681956.png){kind=logo}
_1537501792425.png){kind=logo}
.png1510553097518){kind=logo}
_1574140989530.png){kind=logo}
_1576642991749.png){kind=logo}
